2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Multiple Myeloma
38
Lymphoma, Non-Hodgkin
32
Leukemia, Myeloid, Acute
26
Hodgkin Disease
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
13
Lymphoma
12
Myelodysplastic Syndromes
11
Leukemia, Lymphocytic, Chronic, B-Cell
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms, Plasma Cell
6
Leukemia
6
Recurrence
3
Pancreatic Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Hematologic Neoplasms
3
Gliosarcoma
3
Glioblastoma
3
Warts
2
Sezary Syndrome
2
Neutropenia
2
Myeloproliferative Disorders
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Hairy Cell
2
Infections
2
Immunologic Deficiency Syndromes
2
Interventions
Dexamethasone
12
Bortezomib
9
Lenalidomide
7
Cyclophosphamide
5
isatuximab
3
fludarabine
3
daratumumab
3
Granulocyte Colony-Stimulating Factor
3
pomalidomide
2
filanesib
2
dacetuzumab
2
Tacrolimus
2
Steroids
2
Injections, Subcutaneous
2
Filgrastim
2
Clinical Protocols
2
Calcium Dobesilate
2
Alemtuzumab
2
plerixafor
1
ofatumumab
1
nirogacestat
1
fludarabine phosphate
1
ficlatuzumab
1
epratuzumab
1
birtamimab
1
Zoledronic Acid
1
Whole-Body Irradiation
1
Vorinostat
1
Tissue Banks
1
Thalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Paraproteinemias
×
plerixafor
×
Clear all
NCT01186224
2025-03-17
PHANTASTIC
University of Liverpool
Phase NA
Completed
60 enrolled